EPO published patent application EP3658156A1 filed by Geron Corporation covering a telomerase inhibitor composition (A61K31/7125) for treating myelodysplastic syndrome. Inventors include Rizo and Bussolari. The designation covers 31 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.

Patent publications do not create immediate compliance obligations. Pharmaceutical companies developing telomerase inhibitors or treating myelodysplastic syndromes should review this filing to assess potential freedom-to-operate implications. Competitors may file observations during the examination phase or evaluate prior art. No action is required for entities not developing competing products in this therapeutic space.